Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription 17.08.2026 1 AJR Am J Roentgenol 3 Biochem Biophys Res Commun 4 BMC Gastroenterol 2 Cancer Res 1 Dig Dis Sci 1 Endoscopy 1 Gastroenterology 1 Hepatology 1 Indian J Gastroenterol 1 J Gastroenterol 3 J Gastroenterol Hepatol 4 J Hepatol 1 Oncogene 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. ACORD MR, Ro E, Alazraki AL, Bondoc A, et al
   Pediatric Liver Transplant: Anatomic, Imaging, and Surgical Considerations-A Report of the Pediatric LI-RADS Working Group, From the AJR Special Series on Critical Anatomy.
   AJR Am J Roentgenol. 2025 Aug 27. doi: 10.2214/AJR.25.33506.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

2. LIU Y, Qiao L
   The role of the LPC/ATX/LPA axis in metabolic dysfunction-associated steatotic liver disease.
   Biochem Biophys Res Commun. 2026;831:154330.
   PubMed         Abstract available
   
   
3. ZHANG Y, Liu L
   FOXM1 knockdown suppresses hepatoblastoma progression and glycolysis by inhibiting the Wnt/beta-catenin pathway.
   Biochem Biophys Res Commun. 2026;833:154360.
   PubMed         Abstract available
   
   
4. ZHANG Z, Kumamoto S, Johmura Y, Nakano Y, et al
   Selective ablation of p16(Ink4a)-lineage hepatocytes attenuates hepatic steatosis in diet-induced MASH.
   Biochem Biophys Res Commun. 2026;833:154400.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

5. RAMADAN AM, El-Wakeel LM, Adel A, Abdel-Wahab M, et al
   Effect of high dose N-acetyl cysteine supplementation on markers of oxidative stress and insulin resistance in non-diabetic patients with metabolic dysfunction associated steatotic liver disease: a randomized controlled trial.
   BMC Gastroenterol. 2026;26:500.
   PubMed         Abstract available
   
   
6. NI ZB, Huang LZ, Yao QR, Li Q, et al
   Association of red blood cell distribution width to albumin ratio with all-cause and cardiovascular mortality among adults with MASLD.
   BMC Gastroenterol. 2026;26:502.
   PubMed         Abstract available
   
   
7. WU X, Hou X, Yin J, Li Y, et al
   Association of a novel Fat-Muscle-BMI Index (FMBI) with NAFLD, liver fibrosis, and atherosclerotic cardiovascular disease risk: a cross-sectional study in 1,592 Chinese adults.
   BMC Gastroenterol. 2026;26:501.
   PubMed         Abstract available
   
   
8. QI L, Li B, Xue J, Wu X, et al
   Applications of machine learning in the diagnosis of non-alcoholic fatty liver disease: a systematic review and meta-analysis.
   BMC Gastroenterol. 2026;26:505.
   PubMed         Abstract available
   
   

   
   Cancer Res

9. SRIRAMAREDDY S, Siddarajappa N, Park JS, Nguyen T, et al
   GDF15 Reprograms the Microenvironment to Drive Liver Metastasis of Uveal Melanoma.
   Cancer Res. 2026 May 28. doi: 10.1158/0008-5472.CAN-25-0536.
   PubMed         Abstract available
   
   
10. JIANG F, Chen L, Yang YC, Wang XM, et al
    Retraction: CYP3A5 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Regulating mTORC2/Akt Signaling.
    Cancer Res. 2026;86:4187-4188.
    PubMed        
    
    

    
    Dig Dis Sci

11. ONG N, Wong F
    Albumin in the Management of Hepatorenal Syndrome-Acute Kidney Injury: Is There Ever Too Much?
    Dig Dis Sci. 2026 Aug 11. doi: 10.1007/s10620-026-10169.
    PubMed         Abstract available
    
    

    
    Endoscopy

12. HARA H, Onodera K, Nemoto J, Yokobori S, et al
    Antegrade stent placement and stent-in-stent placement via endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2026 Aug 11. doi: 10.1055/a-2926-9099.
    PubMed        
    
    

    
    Gastroenterology

13. YIN D, Vazquez Salgado AM, Cai C, Wang AW, et al
    Liver regeneration CRISPR screen identifies E3 ligase NEURL1B regulates hepatocyte mitosis by destabilizing microtubule organizing centers.
    Gastroenterology. 2026 Aug 14:S0016-5085(26)07156.
    PubMed         Abstract available
    
    

    
    Hepatology

14. PENG Q, Wang S, Zhang Y, Luo Y, et al
    Hepatocyte hnRNPK preserves mitochondrial integrity to restrain liver injury and fibrosis.
    Hepatology. 2026 Aug 10. doi: 10.1097/HEP.0000000000001836.
    PubMed         Abstract available
    
    

    
    Indian J Gastroenterol

15. CHATTERJEE A
    Comment on non-invasive tools may better predict esophageal varices and their management.
    Indian J Gastroenterol. 2026 Aug 13. doi: 10.1007/s12664-026-02051.
    PubMed        
    
    

    
    J Gastroenterol

16. ZHOU LX, Wan BY, Dong H, Shi AL, et al
    Reply to: comment on "Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection".
    J Gastroenterol. 2026 Aug 10. doi: 10.1007/s00535-026-02497.
    PubMed        
    
    

    
    J Gastroenterol Hepatol

17. OGHENETEGA A, Ghaffar A, Khokhar ME, Opene C, et al
    Methodological Considerations in Real-World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2026 Aug 14. doi: 10.1111/jgh.70673.
    PubMed        
    
    
18. LAU SY, Kok VS, Tan SS, Adnan SD, et al
    The Malaysian Society of Gastroenterology and Hepatology Consensus Statements on Prevention and Early Detection of Hepatocellular Carcinoma in Malaysia.
    J Gastroenterol Hepatol. 2026 Aug 14. doi: 10.1111/jgh.70643.
    PubMed         Abstract available
    
    
19. NAJAF DE, Siddique A, Shah HM, Ullah T, et al
    Beyond Repositionability: Rethinking Clinical Value and Stent Selection in EUS-Guided Hepaticogastrostomy.
    J Gastroenterol Hepatol. 2026 Aug 14. doi: 10.1111/jgh.70666.
    PubMed        
    
    

    
    J Hepatol

20. HARRISON K, Nulty J, Kyrana E, Dhawan A, et al
    Evaluating the translational feasibility and safety of IL-22 driven long-term hepatocyte expansion.
    J Hepatol. 2026 Aug 13:S0168-8278(26)02850-3. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
21. ARGEMI J, Campani C
    Decoding Primary Refractoriness to Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma: The Myeloid Frontier.
    J Hepatol. 2026 Aug 13:S0168-8278(26)02847-3. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
22. ZHANG H, Wang S
    Evaluating the Limitations of Hepatic SIDT1 and DTWD2 as Indicators of Impaired GlycoRNA Biogenesis in MASLD.
    J Hepatol. 2026 Aug 13:S0168-8278(26)02844-8. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
23. WELLS G, O'Brien A
    Non-selective Beta-Blockers in Cirrhosis and AKI: Time to Reconsider Routine Withdrawal?
    J Hepatol. 2026 Aug 13:S0168-8278(26)02848-5. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    

    
    Oncogene

24. JEON S, Shin E, Ha JW, Na MJ, et al
    CSTF2-mediated 3'UTR shortening drives oncogenic activation of GPC3 in hepatocellular carcinoma.
    Oncogene. 2026 Aug 10. doi: 10.1038/s41388-026-03937.
    PubMed         Abstract available
    
    

    
    PLoS One

25. MENG Q, Wang X, Zhang Y, Pushpakom S, et al
    A chemically optimized, GalNAc-conjugated siRNA targeting HSD17B13 demonstrates efficacy in a human 3D organoid model of MASH, showcasing an alternative to animal testing.
    PLoS One. 2026;21:e0354751.
    PubMed         Abstract available
    
    
26. FENG J, Liu Z, Sun H
    Integrative bioinformatics analysis identifies gut microbiota-derived metabolite-associated immune candidate targets in high-risk primary biliary cholangitis.
    PLoS One. 2026;21:e0356008.
    PubMed         Abstract available
    
    
27. WANG T, Gallagher I, Park J, Li Y, et al
    The impact of short-term reduction in hepatic triglycerides on vascular health in adults with or at risk of metabolic dysfunction-associated steatotic liver disease.
    PLoS One. 2026;21:e0345338.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum